Intravenous immunoglobulin therapy for SLE

Rozman, Ziv; Zandman‐Goddard, Gisele

doi:10.2217/ebo.11.328

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To reduce AEs, a single dose of hydrocortisone 100 to 200 mg should be administered on day 1 before initiation of the IVIG therapy. Treatment with a single dose of low-molecular-weight (LMW) heparin before IVIG initiation may prevent possible thromboembolic AEs [51]. Low-dose IVIG therapy (400 mg/kg over 1 day every 3 to 4 weeks) is beneficial for organ-specific disease, predominantly neurological conditions [50].…”

Section: Methodsmentioning

confidence: 99%

Biologic therapy for autoimmune diseases: an update

Rosman

Shoenfeld

Zandman‐Goddard

2013

BMC Med

Self Cite

203

157

View full text Add to dashboard Cite

Biologic therapies for rheumatologic diseases, which are targeted at molecules involved in the mechanisms of the immune system, provide an alternative to the existing treatment methods of disease-modifying anti-rheumatic drugs and other immunosuppressive medications. However, the current drawbacks of biologic therapies, including the inconvenience of intravenous administration, the high costs of these drugs, and the adverse events associated with them, prevent their wide use as first-line medications. This review provides an update of the recent literature on the new biologic therapies available. The review concentrates on nine drugs: tocilizumab, rituximab, ofatumumab, belimumab, epratuzumab, abatacept, golimumab, certolizumab, and sifalimumab, which are used as therapies for rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, systemic sclerosis, or vasculitis.

show abstract

Section: Methodsmentioning

confidence: 99%